The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2026 | Temporal trends in progression risk in smoldering myeloma: insights into a review
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses a recent review exploring temporal trends in progression risk in smoldering myeloma, noting that in earlier studies, many patients were miscategorized as high risk, primarily due to limited access to MRI and PET-CT. Prof. Ludwig is optimistic that future research will help refine the definition of high risk and, in the meantime, advises clinicians to monitor hemoglobin and paraprotein trends to determine whether a patient is eligible for therapy. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
